ArticleCell2021
COVID-19-neutralizing antibodies predict disease severity and survival.
Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 492 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
492 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Serological response following COVID-19 vaccines in patients living with HIV: a dose-response meta-analysis.Scientific reports · 2023Pooled it
- Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study.Frontiers in immunology · 2025Trial
- Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles.Scientific reports · 2023Trial
- Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.Nature communications · 2023Trial
- A predictive model for rapid assessment of protective efficacy against emerging SARS-CoV-2 variants.Infectious Disease Modelling · 2026Article
- High Frequencies of Senescent and Exhausted Natural Killer Cells and SARS-CoV-2-Specific Memory CD8Viruses · 2026Article
- Pre-vaccine sentinel antibodies predict blunted vaccine responses.Cell press blue · 2026Article
- Distinct CD8iScience · 2026Article
- Anti-spike IgG Avidity Enhances Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2: A Prospective Study of Primary Infections and Immunizations.The Journal of infectious diseases · 2026Article
- Prefusion-stabilized SARS-CoV-2 spike reshapes antigenic hierarchy and antibody targeting against conserved and occluded epitopes.NPJ vaccines · 2026Article
- Post-Pandemic Neutralizing Antibody Responses to SARS-CoV-2 D614G Variant in Rural and Urban Ghana.Viruses · 2026Article
- Protocol for lentiviral engineering and multi-omic characterization of human kidney tubuloids.STAR protocols · 2026Article
- Evaluating southern pigtail macaques as an immunological model for human antibody responses.Scientific reports · 2026Article
- SARS-CoV-2 fusion-peptide-directed antibodies are elicited by natural infection and can mediate broad sarbecovirus neutralization.Cell reports · 2026Article
- Host proteins associated with strong neutralizing SARS-CoV-2 antibody responses in a South African cohort.Communications medicine · 2026Article
- Article
- Case Report: Successful treatment of recurrent COVID-19 with intravenous immunoglobulin in a patient with rituximab-induced B-cell depletion and restoration of Fc-mediated effector functions.Frontiers in immunology · 2026Article
- Paying Upfront: Successful Initial Infections Protect Against Severe Future Infections.Integrative organismal biology (Oxford, England) · 2026Article
- Impaired serum neutralization and death in Omicron-infected critically ill patients: insights from the French SEVARVIR prospective, multicenter cohort study.Intensive care medicine experimental · 2025Article
- Magnetic bead-based electrochemical surrogate virus neutralization test for quantification of antibody neutralizing efficiency.Biosensors & bioelectronics · 2025Article
432 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
20 authors.
Funding
Abstract
Coronavirus disease 2019 (COVID-19) exhibits variable symptom severity ranging from asymptomatic to life-threatening, yet the relationship between severity and the humoral immune response is poorly understood. We examined antibody responses in 113 COVID-19 patients and found that severe cases resulting in intubation or death exhibited increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high anti-receptor binding domain (RBD) antibody levels. Although anti-RBD immunoglobulin G (IgG) levels generally correlated with neutralization titer, quantitation of neutralization potency revealed that high potency was a predictor of survival. In addition to neutralization of wild-type SARS-CoV-2, patient sera were also able to neutralize the recently emerged SARS-CoV-2 mutant D614G, suggesting cross-protection from reinfection by either strain. However, SARS-CoV-2 sera generally lacked cross-neutralization to a highly homologous pre-emergent bat coronavirus, WIV1-CoV, which has not yet crossed the species barrier. These results highlight the importance of neutralizing humoral immunity on disease progression and the need to develop broadly protective interventions to prevent future coronavirus pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.